Market Forecast

Meningococcal Vaccines Market size is projected to be worth USD 6.80 billion by 2032, registering a CAGR of 7.3% during the forecast period 2023 – 2032.

The Market for meningococcal infection vaccines is witnessing steady expansion, driven by the pressing need to combat various strains of meningococcal bacteria responsible for causing severe infections. Meningococcal infection vaccines target specific serogroups of the bacteria, offering protection against meningococcal diseases like septicemia and meningitis. These vaccines are integral components of immunization strategies, especially in regions where meningococcal infections pose significant health risks. Governments and healthcare organizations are increasingly emphasizing the importance of meningococcal vaccination to mitigate the burden of meningococcal disease outbreaks. As a result, pharmaceutical manufacturers are investing in research and development efforts to enhance the efficacy and accessibility of meningococcal infection vaccines, thereby contributing to the overall growth of the meningococcal vaccines market.

The Meningococcal Vaccines Market is experiencing significant growth, driven by the rising incidence of meningococcal diseases globally. Meningococcal diseases, caused by the bacterium Neisseria meningitidis, can lead to serious illnesses such as meningitis and septicemia, posing a substantial public health burden. Increasing awareness about the importance of vaccination, coupled with government initiatives to incorporate meningococcal vaccines into routine immunization programs, is fueling market expansion. Additionally, advancements in vaccine technology, including the development of conjugate vaccines offering broader protection against multiple meningococcal serogroups, are further propelling market growth. Key players in the industry are investing in research and development to innovate new vaccine formulations with improved efficacy and safety profiles, catering to the evolving needs of healthcare systems worldwide.

Moreover, the Meningococcal Vaccines Market is witnessing notable regional variations in demand and adoption rates, with developed regions showing higher uptake compared to developing economies. Factors such as vaccine affordability, accessibility, and healthcare infrastructure influence the distribution and utilization of meningococcal vaccines across different geographies. Collaborations between governments, non-profit organizations, and pharmaceutical companies are instrumental in expanding vaccine coverage, particularly in low- and middle-income countries where meningococcal diseases pose a significant public health challenge. Looking ahead, the market is poised for continued growth, driven by ongoing efforts to address unmet medical needs, expand vaccination coverage, and develop innovative vaccine formulations to combat meningococcal diseases effectively.

Competitive landscape

The meningococcal vaccines market players are below.

  • Baxter international
  • Pfizer Inc.
  • Sanofi S.A.
  • Novartis Pharmaceuticals Inc.
  • JN-International Medical Corporation
  • Serum Institute of India Ltd.
  • GlaxoSmithKline
  • BIO-MED
  • OthersTop of Form

Meningococcal Vaccines Market Segmentation

By treatment, the market is segmented into Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine.

Meningococcal A conjugate vaccine is significantly used in mass campaigns across affected regions like Africa. Since 2010, the vaccine has significantly decreased meningococcal disease incidence in the region. However, the demand for meningococcal A conjugate in the country remains uncertain given that national immunization program adoptions are based on the timing of Gavi funding decisions, the country’s readiness, and competing for vaccine introduction priorities.

In the polysaccharide segment, products such as MenACWY vaccines are in high demand. MenACWY vaccine is the most desirable combination, given its broader serotype coverage. MenACWY specifically has nine products that are available across polysaccharide and conjugate product segments, but conjugate products are suggested for use in routine immunization activities.

Moreover, the demand and supply of Subcap MenB vaccines is restricted to HICs and influenced by their acceptance into NIPs. Improved uptake of MenB vaccines is expected in the coming years but will likely be moderate and limited to high-income markets given the high price and competing interest of introducing MenACWY conjugate.

By end-user, the market is segmented into Hospital & Clinical, Research Laboratories, and Academic Institutes

Hospitals and clinics control the global meningococcal vaccines market insights. The high growth of hospitals and clinics segment is attributed to the increasing application of vaccines in these healthcare facilities in conjunction with the growing prevalence and incidence of the meningococcal disease.

Moreover, research laboratories and academic institutes take up the second-largest share due to the boost in research and development in the market.

By region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

In the global market, China is expected to have the largest market share, which accounts for approximately 35% of the global demand. This is primarily due to polysaccharide products, which currently comprise 84% of China’s demand. Chinese suppliers presently focus only on meeting the demand of the domestic market, but some of the manufacturers have indicated interest in the global market as well. The dynamic product pipeline with several multivalent conjugate products in development may trigger changes in the future supply mix of the Chinese market. Moreover, in China, non-routine use (excluding campaigns) accounts for an estimated 9 million doses in 2019, which may help to sustain the huge market share in the forecast period.

UNICEF foresees all 26 African countries in the meningitis belt, which have completed mass campaigns in 2016. In 2015, seven countries in the region were introduced with meningococcal A conjugate vaccine through their mass campaigns and targeted a population of 233 million. Further, during 2016-2018, UNICEF introduced meningococcal A conjugate vaccine in 26 countries. Ghana was the first country to be introduced with the vaccine into its RI schedule in 2016. Also, four other countries including Mali, Niger, Nigeria, and Sudan introduced the vaccine into RI programs in 2016.

For more information, Please Visit us @ Market Research Future